**Suppl. table 2: Baseline clinical and echocardiographic characteristics in the subgroup of patients with LGE-quantification by CMR**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total cohort (n=40)** | **LGE below median (≤24g)**  **(n=20)** | **LGE above median (>24g) (n=20)** | **P** |
|  |  |  |  |  |
| **Fibrosis by histology,** *%* | 20±4 | 14.1±20.4 | 27.6±26 | 0.08 |
| **Age,** *y* | 79±6 | 80±6 | 77±6 | 0.14 |
| **Sex, female,** *n (%)* | 12 (30) | 6 (30) | 6 (30) | 1.0 |
|  |  |  |  |  |
| **Comorbidities** |  |  |  |  |
| **Coronary artery disease,** *n %)* | 27 (68) | 12 (60) | 15 (75) | 0.5 |
| **Prior PCI,** *n (%)* | 18 (45) | 9 (45) | 9 (45) | 1.0 |
| **Prior CABG,** *n (%)* | 7 (18) | 4 (20) | 7 (35) | 0.5 |
| **Prior myocardial infarction,** *n (%)* | 10 (25) | 3 (15) | 7 (35) | 0.5 |
| **Atrial fibrillation,** *n (%)* | 13 (33) | 7 (35) | 6 (30) | 1.0 |
| **Peripheral vascular disease** | 12 (30) | 4 (20) | 8 (40) | 0.3 |
| **Prior cerebral ischem. event,** *n(%)* | 2 (5) | 1 (5) | 1 (5) | 1.0 |
| **Diabetes,** *n (%)* | 16 (40) | 7 (35) | 9 (45) | 0.7 |
| **CKD, GFR < 60 mL/min,** *n (%)* | 16 (40) | 9 (45) | 7 (35) | 0.7 |
|  |  |  |  |  |
| **Echo parameters** |  |  |  |  |
| **AS subtype:** |  |  |  |  |
| * **Moderate AS,** *n* | 2 | 2/2 (100) | 0 | 0.33 |
| * **NEF-HG AS,** *n (%)* | 13 | 7/13 (54) | 6/13 (46) | 1.0 |
| * **LEF-HG AS,** *n (%)* | 6 | 2/6 (33) | 4/6 (67) | 0.56 |
| * **LEF LG AS,** *n (%)* | 12 | 4/12 (33) | 8/12 (67) | 0.22 |
| * **PLF-LG AS,** *n (%)* | 7 | 5/7 (71) | 2/7 (29) | 0.29 |
| **LV-EF,** *%* | 49±15 | 54±9 | 44±17 | 0.02 |
| **LVEDV,** *ml* | 92±39 | 80±30 | 104±44 | 0.05 |
| **LVEDVi,** *ml/m² BSA* | 47±19 | 40±14 | 53±22 | 0.03 |
| **Stroke Volume Index,** *ml/m²* | 37±9 | 36±9 | 37±9 | 0.59 |
| **LAVI,** *ml/m² BSA* | 50±15 | 48±17 | 52±13 | 0.49 |
| **LVMI,** *g/m² BSA* | 153±46 | 143±43 | 163±48 | 0.16 |
| **LVEDD,** *mm* | 47±8 | 44±7 | 50±9 | 0.03 |
| **Normal geometry,** *n (%)* | 0 | 0 | 0 | 1.0 |
| **Concentric remodelling,** *n (%)* | 7 (18) | 5 (25) | 2 (10) | 0.41 |
| **Concentric hypertrophy,** *n(%)* | 27 (68) | 14 (70) | 13 (66) | 1.0 |
| **Eccentric hypertrophy,** *n (%)* | 6 (15) | 1 (5) | 5 (25) | 0.18 |
| **Global long. strain,** *%* | -14.6±4.7 | -16.5±3.5 | -13.0±5.0 | 0.02 |
| **Mean Gradient,** *mmHg* | 37±14 | 35±11 | 40±17 | 0.26 |
| **Aortic valve area (AVA),** *cm²* | 0.74±0.16 | 0.75±0.14 | 0.73±0.18 | 0.72 |
|  |  |  |  |  |

* 2-group-comparisons: t-test for continuous variables; fisher’s exact test for categorical variables

PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; CKD: chronic kidney disease; STS: Society of Thoracic Surgeons; NYHA: New York Heart Association; LV-EF: left ventricular ejection fraction; vmax: maximum aortic velocity; AVA: aortic valve are; AVAi: indexed aortic valve area, AVA/BSA; BSA: body surface area; MR: mitral regurgitation